Peer-reviewed veterinary case report
Mesenchymal stem cells improve depressive disorder via inhibiting the inflammatory polarization of microglia.
- Journal:
- Journal of psychiatric research
- Year:
- 2024
- Authors:
- Wang, Qianqian et al.
- Affiliation:
- Nanjing University of Chinese Medicine · China
- Species:
- rodent
Abstract
Depressive disorder (DD) ranks among the most prevalent, burdensome, and costly psychiatric conditions globally. It manifests through a range of emotional, cognitive, somatic, and behavioral symptoms. Mesenchymal Stem Cells (MSCs) have garnered significant attention due to their therapeutic potential via immunomodulation in neurological disorders. Our research indicates that MSCs treatment demonstrates a notable effect on a Chronic Unpredictable Mild Stress (CUMS)-induced DD model in mice, surpassing even Fluoxetine in its antidepressant efficacy. MSCs mitigate DD by inhibiting central nervous system inflammation and facilitating the conversion of microglial cells into an Arg1anti-inflammatory state. The MSCs-derived TGF-β1 is crucial for this Arg1microglial cell transformation in DD treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/39270422/